睿知中国医院研究地图
候选清单

正在招募乳腺癌III期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer

ClinicalTrials.gov 上登记的一项乳腺癌开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心复旦大学附属肿瘤医院Fudan University Shanghai Cancer Center上海医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06846437,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 8

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(8 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. 3.Patients with unresectable locally advanced or metastatic breast cancer confirmed by histology or cytology.

    入选标准第 3 条

    4.Confirmed to be HER2 positive (HER2-positive is defined as IHC 3+ or IHC 2+ with ISH positive) by the pathology department of participating study center.

    入选标准第 4 条

    5.Have received treatment regimen including trastuzumab (allowed marketed trastuzumab biosimilars) or inetetamab with radiologic or pathologic progression/ relapse during the advanced stage, during neoadjuvant or adjuvant therapy, or within 12 months after treatment.

    入选标准第 5 条

    7.Had radiologic and/or pathologic progression or intolerance of the latest systemic anti-tumor therapy.

    入选标准第 7 条

  3. 1. Have previously been treated with an anti-HER2 ADC loaded with topoisomerase I inhibitors or medenosin derivative 1 (DM1) or have relapsed after receiving such therapy during or within 12 months after the adjuvant/neo-adjuvant setting or in the advanced stage.

    排除标准第 1 条

  4. 5.Has not recovered from adverse reactions caused by previous anti-tumor treatments to ≤ Grade 1 (refer to NCI CTCAE 5.0) or baseline (excluding grade 2 alopecia, hyperpigmentation, simple laboratory test abnormalities, and other toxicity for a non-safety risk by investigators).

    排除标准第 5 条

    6.Received immunotherapy, macromolecular targeted therapy or other anti-tumor biological therapy within 4 weeks before randomization, or received palliative radiotherapy, endocrine therapy, cytotoxic drug chemotherapy and small molecular targeted drug therapy within 2 weeks before randomization, or received traditional Chinese medicine preparations with anti-tumor indications within 2 weeks before randomization.

    排除标准第 6 条

    10.History of LVEF < 40% during prior anti-HER2 drug therapy or symptomatic congestive heart failure (CHF).

    排除标准第 10 条

    12.History of (non-infectious) interstitial lung disease/pneumonitis requiring therapy or grade ≥3 interstitial lung disease/ pneumonitis during previous anti-tumor treatments.

    排除标准第 12 条

    16.Received a potent inhibitor of CYP3A4 within 14 days prior to randomization or during study treatment.

    排除标准第 16 条

  5. 9.ECOG PS of 0 - 1.

    入选标准第 9 条

  6. 8.At least one extracranial measurable lesion at baseline according to RECIST 1.1 criteria.

    入选标准第 8 条

  7. 2.History of any other malignant tumors within three years before randomization.

    排除标准第 2 条

    14. Active hepatitis B or hepatitis C.

    排除标准第 14 条

    15.History of immunodeficiency or HIV antibody test positive at screening.

    排除标准第 15 条

  8. 17.Pregnant or nursing females;

    排除标准第 17 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:化验:血常规、肝肾功能。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06846437,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. 1. Voluntarily agree to participate in the study and sign the informed consent.
  2. 2.Age≥18 years old.
  3. 3.Patients with unresectable locally advanced or metastatic breast cancer confirmed by histology or cytology.
  4. 4.Confirmed to be HER2 positive (HER2-positive is defined as IHC 3+ or IHC 2+ with ISH positive) by the pathology department of participating study center.
  5. 5.Have received treatment regimen including trastuzumab (allowed marketed trastuzumab biosimilars) or inetetamab with radiologic or pathologic progression/ relapse during the advanced stage, during neoadjuvant or adjuvant therapy, or within 12 months after treatment.
  6. 6.Previously treated with taxanes.
  7. 7.Had radiologic and/or pathologic progression or intolerance of the latest systemic anti-tumor therapy.
  8. 8.At least one extracranial measurable lesion at baseline according to RECIST 1.1 criteria.
  9. 9.ECOG PS of 0 - 1.
  10. 10.Patients with adequate organ and bone marrow functions.
  11. 11.Expected survival ≥ 3 months.
  12. 12.Female and male patients of childbearing age agree to take adequate contraceptive measures during and upon completion of the study for 7 months after the last dose of JSKN003 or T-DM1.

排除标准:Exclusion Criteria:

  1. 1. Have previously been treated with an anti-HER2 ADC loaded with topoisomerase I inhibitors or medenosin derivative 1 (DM1) or have relapsed after receiving such therapy during or within 12 months after the adjuvant/neo-adjuvant setting or in the advanced stage.
  2. 2.History of any other malignant tumors within three years before randomization.
  3. 3.With uncontrollable serous effusion within 14 days before randomization, which requires frequent drainage or medical intervention.
  4. 4.Known contraindication to T-DM1or not suitable to receive JSKN003 or T-DM1 by investigator.
  5. 5.Has not recovered from adverse reactions caused by previous anti-tumor treatments to ≤ Grade 1 (refer to NCI CTCAE 5.0) or baseline (excluding grade 2 alopecia, hyperpigmentation, simple laboratory test abnormalities, and other toxicity for a non-safety risk by investigators).
  6. 6.Received immunotherapy, macromolecular targeted therapy or other anti-tumor biological therapy within 4 weeks before randomization, or received palliative radiotherapy, endocrine therapy, cytotoxic drug chemotherapy and small molecular targeted drug therapy within 2 weeks before randomization, or received traditional Chinese medicine preparations with anti-tumor indications within 2 weeks before randomization.
  7. 7.Major organ surgery within 28 days before randomization.
  8. 8.Untreated (including baseline findings) or unstable cerebral parenchymal metastasis, spinal cord metastasis or compression, and cancerous meningitis.
  9. 9.The cumulative amount of previous exposure to anthracyclines has reached the pre-specified dosage.
  10. 10.History of LVEF < 40% during prior anti-HER2 drug therapy or symptomatic congestive heart failure (CHF).
  11. 11.Serious or uncontrolled cardiovascular disease.
  12. 12.History of (non-infectious) interstitial lung disease/pneumonitis requiring therapy or grade ≥3 interstitial lung disease/ pneumonitis during previous anti-tumor treatments.
  13. 13.Active infections requiring intravenous antibiotics, antivirals, or antifungals within 14 days before randomization.
  14. 14. Active hepatitis B or hepatitis C.
  15. 15.History of immunodeficiency or HIV antibody test positive at screening.
  16. 16.Received a potent inhibitor of CYP3A4 within 14 days prior to randomization or during study treatment.
  17. 17.Pregnant or nursing females;
  18. 18.Other reasons enrolled in this clinical trial as considered unsuitable by the investigator.

引自 ClinicalTrials.gov, NCT06846437, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06846437,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06846437